The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-25 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
About 20,000 protein coding genes are expressed in human cells and 60% of these genes are expressed in a normal, adult liver. Over 400 genes are more specifically expressed in the liver, with some 150 genes highly specific for liver tissue. A large fraction of the corresponding liver-specific proteins are mainly expressed in hepatocytes and secreted into the blood and constitute plasma proteins and hepatokines. Other liver-specific proteins are certain liver enzymes such as HAO1 and RDH16, proteins involved in bile synthesis such as BAAT and SLC27A5, and transporter proteins involved in the metabolism of drugs, such as ABCB11 and SLC2A2. Examples of highly liver-specific proteins include apolipoprotein A II, coagulation factors F2 and F9, complement factor related proteins, and the fibrinogen beta chain protein.
=== Aliases === Hodgkin published as "Dorothy Crowfoot" until 1949, when she was persuaded by Hans Clarke's secretary to use her married name on a chapter she contributed to The Chemistry of Penicillin. By then she had been married for 12 years, given birth to three children and been elected a Fellow of the Royal Society (FRS). Thereafter she would publish as "Dorothy Crowfoot Hodgkin", and this was the name used by the Nobel Foundation in its award to her and the biography it included among other Nobel Prize recipients; it is also what the Science History Institute calls her. For simplicity's sake, Hodgkin is referred to as "Dorothy Hodgkin" by the Royal Society, when referring to its sponsorship of the Dorothy Hodgkin fellowship, and by Somerville College, after it inaugurated the annual lectures in her honour. The National Archives of the United Kingdom refer to her as "Dorothy Mary Crowfoot Hodgkin"; on a variety of plaques commemorating places where she worked or lived, e.g. 94 Woodstock Road, Oxford, she is "Dorothy Crowfoot Hodgkin". In 2022, the Department of Biochemistry in Oxford renamed its much expanded building after Hodgkin, calling it the "Dorothy Crowfoot Hodgkin Building".
He reasoned, however, that removing material from either of the sensory or motor zones could give rise to "grave functional disturbance". Instead, by targeting the association centers and creating a "ditch" around the motor region of the temporal lobe, he hoped to break their lines of communication and thus alleviate both mental symptoms and the experience of mental distress.
==== Deep vein thrombosis ==== DVT usually occurs in the veins of the legs, although it can also occur in the deep veins of the arms. Immobility, active cancer, obesity, traumatic damage and congenital disorders that make clots more likely are all risk factors for deep vein thrombosis. It can cause the affected limb to swell, and cause pain and an overlying skin rash. In the worst case, a deep vein thrombosis can extend, or a part of a clot can break off as an embolus and lodge in a pulmonary artery in the lungs, known as a pulmonary embolism. The decision to treat deep vein thrombosis depends on its size, symptoms, and their risk factors. It generally involves anticoagulation to prevents clots or to reduce the size of the clot. Intermittent pneumatic compression is a method used to improve venous circulation in cases of edema or in those at risk from a deep vein thrombosis.
Sources: en.wikipedia.org
==== Agonists ==== Agmatine (putative endogenous ligand at I1; also interacts with NMDA, nicotinic, and α2 adrenoceptors) Apraclonidine (α2 adrenoceptor agonist) 2-BFI (I2 agonist, NMDA antagonist) Cimetidine (I1 agonist, H2 receptor antagonist) Clonidine (I1 agonist, α2 adrenoceptor agonist) LNP-509 LNP-911 7-Me-marsanidine Dimethyltryptamine mCPP Moxonidine Oxymetazoline (I1 agonist, α1 adrenoceptor agonist, α2 partial agonist) Rilmenidine S-23515 S-23757 Tizanidine
The penis is sometimes pierced or decorated by other body art. Other than circumcision, genital alterations are almost universally elective and usually for the purpose of aesthetics or increased sensitivity. Piercings of the penis include the Prince Albert, apadravya, ampallang, dydoe, deep shaft and frenum piercings. Foreskin restoration or stretching is a further form of body modification, as well as implants under the shaft of the penis. Another type of alteration to the penis is genital tattooing. Trans women who undergo sex reassignment surgery have their penis surgically modified into a vagina or clitoris via vaginoplasty or clitoroplasty respectively. Trans men who undergo such surgery have a phalloplasty or metoidioplasty. Other practices that alter the penis are also performed, although they are rare in Western societies without a diagnosed medical condition. Apart from penectomy, perhaps the most radical of these is subincision, in which the urethra is split along the underside of the penis. Subincision originated among Aboriginal Australians, although it is now done by some in the U.S. and Europe.
The Conservative Party launches an investigation into former Foreign Office minister Alan Duncan after an appearance on LBC during which he said the Conservative Friends of Israel was "doing the bidding" of Israeli prime minister Benjamin Netanyahu. Conservative MP Luke Evans identifies himself to police as "a victim of cyber-flashing and malicious communication". 8 April – Ofcom launches an investigation into the 29 March edition of David Lammy's show on LBC to determine whether it broke the rules regarding politicians acting as newsreaders. William Wragg steps down as vice chair of the Conservative Party's 1922 Committee following revelations about the Westminster WhatsApp scam. Richard Tice, leader of Reform UK, defends his party's vetting procedure after 12 general election candidates were deselected for offensive social media posts. 9 April – William Wragg voluntarily resigns the Conservative whip and will sit in Parliament as an independent MP. He also gives up his role on the Public Administration Committee. The brother-in-law of First Minister of Scotland Humza Yousaf appeared at Dundee Sheriff Court charged with abduction and extortion following an incident where a man fell from a block of flats and later died. Three people are arrested after staging a protest outside the London home of Keir Starmer. 10 April – Figures published by the Foreign Office indicate that £4.3bn of its budget for 2023 – roughly a quarter of the overall foreign aid budget for the year – was spent on refugees and asylum seekers in the UK.
The strong tornado widened again and curved northward as it exited Hodonín and moved into a rural area, completely mowing down a large swath of trees as it impacted a patch of forest. Metal truss transmission towers were blown over in this area, crops were damaged in farm fields, and damage along this segment of the path was rated F2. The tornado briefly strengthened again one final time as it struck the village of Pánov at high-end F3 strength. Almost every structure in the small village was damaged in some way, and multiple homes were significantly damaged or destroyed, a few of which were leveled. Outbuildings were destroyed, cars were damaged by flying debris, and large trees were snapped and denuded as well. The tornado continued past Pánov and moved through another densely forested area, weakening back to F2 strength as it flattened another large swath of trees. The tornado continued to weaken, and trees beyond this point were downed at F1 intensity as the tornado continued to the northeast before it abruptly dissipated near Ratíškovice. In all, at least 1,200 buildings were damaged or destroyed by the tornado along its 27.1 kilometer (17 mi)-long path. 6 people were killed by the tornado, and at least 200 more were injured, some critically.
The SBP-Tag will also bind to streptavidin or streptavidin reagents in solution. Applications of these engineered associations include the visualization of specific proteins within living cells, monitoring of the kinetics of the translation of individual proteins in an in vitro translation system, control of the integration of a multi-spanning membrane protein into the endoplasmic reticulum by fusing the SBP-Tag to the N-terminal translocation sequence and then halting integration with streptavidin and restarting integration with biotin. Fluorescent streptavidin reagents (e.g. streptavidin-HRP) can be used to visualize the SBP-tag by immunoblotting of SDS-PAGE. Additionally, antibodies to the SBP-tag are available commercially. The SBP-Tag has been used to reversibly immobilize recombinant proteins onto streptavidin-functionalized surfaces thereby permitting interaction assessment such as by surface plasmon resonance (SPR) techniques with re-use of the functionalized surface. SPR has also been used to compare the SBP-Tag with other streptavidin-binding peptides such as Strep-tag.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.